BMS Decides Against Opdualag Launch In Germany

BMS says that recent reforms to the benefit assessment system have led to the “deterioration” of the German market. 

Uncertain result
BMS Does Not Believe Opdualag Would Perform Well In Benefit Assessment • Source: Shutterstock

Bristol Myers Squibb Company will not launch its advanced melanoma combination treatment Opdualag (nivolumab plus relatlimab) in Germany because it does not believe it would win a favorable outcome in a benefit assessment.

Results of the benefit assessment are important as they subsequently influence the product’s final price.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography